<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="404">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04436458</url>
  </required_header>
  <id_info>
    <org_study_id>FW-COV-002</org_study_id>
    <nct_id>NCT04436458</nct_id>
  </id_info>
  <brief_title>Niclosamide In Moderate COVID-19</brief_title>
  <official_title>Phase 2, Multicentre, Randomized, Double Blind, 2 Arms Placebo-controlled Study in Adults With Moderate COVID-19 With Gastrointestinal Signs and Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Wave Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Wave Bio, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicentre, randomized, double blind, 2 arm placebo-controlled study in
      adults with moderate COVID-19 with gastrointestinal signs and symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the rate of faecal SARS-CoV-2 virus clearance (rectal swab or stool sample) assessed by RT-PCR in the niclosamide group, compared to the placebo group</measure>
    <time_frame>From Day 1 to 42</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Niclosamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continued SOC therapy together with Niclosamide tablets for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Continued SOC therapy together with placebo tablets matching niclosamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niclosamide Oral Tablet</intervention_name>
    <description>Continued SOC therapy together with niclosamide TID for 14 days</description>
    <arm_group_label>Niclosamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Continued SOC therapy together with placebo tablets matching niclosamide for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients hospitalized for treatment of COVID-19 with or without pneumonia, who are
             expected to remain in hospital at least seven days after the randomization and who
             accept continuing to be assessed for the study procedures (home or outpatient unit) up
             to 6 weeks in case of discharge.

          -  Patients who prior to developing COVID-19 usually have normal bowel habits defined as
             at least 3 stools per week and no more than 3 stools per day.

          -  SARS-CoV-2 infection confirmed by RT-PCR in rectal swab (or stool test) â‰¤2 days before
             randomization by local or central lab.

          -  Diarrhea defined as at least 3 watery stools in the last 24 hours prior to enrolment

        Exclusion Criteria:

          -  At the time of randomization patients requiring ICU admission or patients with severe
             respiratory insufficiency requiring mechanical ventilation or with rapid worsening of
             respiratory function leading to expectation for mechanical ventilation or ICU
             admission.

          -  Evidence of rapid clinical deterioration or existence of any life-threatening
             co-morbidity or any other medical condition which, in the opinion of the investigator,
             makes the patient unsuitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tony Opipari, M.D.</last_name>
    <phone>734-546-0228</phone>
    <email>tony@firstwavebio.com</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niclosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

